This week, the last 2023’ NephJC resurfaces an old dilemma, in a different SPACE- non-cardiac surgery. Should we STOP ACEi, or do we know better?
Background
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
Background
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
